Biostage Q2 net loss narrows to $0.4M; cash $0.5M, funding into Q3 2021

Harvard Apparatus Regenerative Technology, Inc.

2022-Q2 EPS reported -$0.13

Net loss of $0.4M ($0.04 per share) vs $1.2M loss in Q2 2020.
Improvement due to lower R&D, lower G&A, and $0.4M PPP loan forgiveness gain.
Cash on-hand of $0.5M as of June 30, 2021; expects to fund operations into Q3 2021.
No conference call held; company plans future call for clinical and business plans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.